Tilray Brands vs Trulieve Cannabis
TLRY and TRLV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TLRY and TRLV compare
Trulieve Cannabis is the larger company, worth 5.8 times as much as Tilray Brands ($2.1B against $359M).
Tilray Brands grew revenue faster over the last twelve months (15.9% versus −9.1% for Trulieve Cannabis).
Tilray Brands scores higher on the StockData Score (11 against 4 for Trulieve Cannabis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TLRY | TRLV |
|---|---|---|
| Size and price | ||
| Market cap | $359M | $2.1B |
| Share price | $2.43 | $10.90 |
| Change, 1 year | −80.2% | 58.4% |
| Change, 5 years | −97.8% | −62.6% |
| Beta (5Y) | 1.53 | 1.14 |
| Employees | 3,595 | 5,000 |
| StockData Score | ||
| Total score | 11 (better) | 4 |
| Valuation score | 3 (better) | 2 |
| Growth score | 3 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 1.9× |
| P/B | 0.2× | – |
| P/FCF | – | 11.2× |
| FCF yield | – | 9.0% |
| Fair value | $17.55 | $12.11 |
| Margin of safety | 86.2% (better) | 10.0% |
| Growth | ||
| Revenue growth (TTM) | 15.9% (better) | −9.1% |
| Revenue growth, 5Y average | 40.5% (better) | 17.8% |
| Profitability | ||
| Gross margin | 29.1% | 60.6% (better) |
| Operating margin | −9.3% (better) | −25.6% |
| Net margin | −17.1% | – |
| FCF margin | – | 17.4% |
| Return on equity | −10.4% | – |
| Return on invested capital | −5.0% | – |
| Financial health | ||
| Debt / equity | 0.08 | – |
| Interest coverage | – | −5.3× |
| Current ratio | 1.88 | 5.52 (better) |
| Altman Z-score | −2.23 | 0.41 (better) |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Buyback yield | −43.9% | – |
| Shareholder yield | −43.9% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 9.5% | 20.1% |
| Held by insiders | 2.0% | 5.3% |
| Insider net buying, 12 months | −$164K (better) | −$14.7M |
| Short interest, % of float | 13.5% | 2.1% |
Go deeper
- TLRY stock overview
- TLRY income statement
- TLRY valuation and score
- TRLV stock overview
- TRLV income statement
- TRLV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.